MA29459B1 - Vaccins - Google Patents

Vaccins

Info

Publication number
MA29459B1
MA29459B1 MA30387A MA30387A MA29459B1 MA 29459 B1 MA29459 B1 MA 29459B1 MA 30387 A MA30387 A MA 30387A MA 30387 A MA30387 A MA 30387A MA 29459 B1 MA29459 B1 MA 29459B1
Authority
MA
Morocco
Prior art keywords
vaccines
complexed
subunit
adjuvant
coli
Prior art date
Application number
MA30387A
Other languages
English (en)
Inventor
Marianne Dewerchin
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510280A external-priority patent/GB0510280D0/en
Priority claimed from GB0524407A external-priority patent/GB0524407D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29459B1 publication Critical patent/MA29459B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION DE VACCIN COMPRENANT LA SOUS-UNITÉ B DE LA TOXINE THERMOLABILE D'E. COLI OU UN DÉRIVÉ DE CETTE DERNIÈRE PRÉSENTANT UNE HOMOLOGIE SUPÉRIEURE OU ÉGALE À 90 %, COMPLEXÉE AVEC UN ANTIGÈNE ET UN ADJUVANT
MA30387A 2005-05-19 2007-11-20 Vaccins MA29459B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0510280A GB0510280D0 (en) 2005-05-19 2005-05-19 Vaccines
GB0524407A GB0524407D0 (en) 2005-11-30 2005-11-30 Vaccines

Publications (1)

Publication Number Publication Date
MA29459B1 true MA29459B1 (fr) 2008-05-02

Family

ID=37431620

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30387A MA29459B1 (fr) 2005-05-19 2007-11-20 Vaccins

Country Status (13)

Country Link
US (1) US20090035330A1 (fr)
EP (1) EP1881844A2 (fr)
JP (1) JP2008540625A (fr)
KR (1) KR20080018201A (fr)
AU (1) AU2006248725A1 (fr)
BR (1) BRPI0610061A2 (fr)
CA (1) CA2608979A1 (fr)
EA (1) EA200702254A1 (fr)
IL (1) IL187008A0 (fr)
MA (1) MA29459B1 (fr)
MX (1) MX2007014390A (fr)
NO (1) NO20075727L (fr)
WO (1) WO2006123155A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (fr) * 2001-02-01 2002-08-07 Institut Curie Support universel pour le ciblage de molécules sur des cellules exprimant le récepteur Gb3
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
BRPI0719865A2 (pt) 2006-10-12 2016-03-15 Angeletti P Ist Richerche Bio molécula de ácido nucleico, proteína de fusão purificada, vetor, célula hospedeira, processo para expressar uma proteína de fusão, e, método para tratar um paciente sofrendo de ou predisposto a um câncer
EP2034022A1 (fr) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Récepteur de la lipocaline soluble liant le leukotriène B4 issu de Ixodes ricinus
EP2045263A1 (fr) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification et caractérisation moléculaire de métalloprotéases salivaires exprimées dans les glandes salivaires de la tique
WO2010144797A2 (fr) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
WO2010147268A1 (fr) * 2009-06-19 2010-12-23 아이진 주식회사 Vaccin contre le cancer du col de l'uterus
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
WO2015089707A1 (fr) 2013-12-16 2015-06-25 财团法人农业科技研究所 Plasmide, procédé et kit de production de sous-unité b de l'entérotoxine instable à la chaleur
BR112017002496A2 (pt) * 2014-08-08 2018-02-20 Idemitsu Kosan Co agente de controle contra a síndrome reprodutiva e respiratória porcina
ES2882827T3 (es) 2014-10-07 2021-12-02 Cytlimic Inc Péptido inductor de inmunidad derivado de HSP70
BR112017018703A2 (pt) 2015-03-09 2018-04-17 Cytlimic Inc. peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
JP6311094B2 (ja) 2015-04-07 2018-04-18 サイトリミック株式会社 医薬
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN111333734B (zh) * 2020-03-31 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) * 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines

Also Published As

Publication number Publication date
CA2608979A1 (fr) 2006-11-23
WO2006123155A2 (fr) 2006-11-23
KR20080018201A (ko) 2008-02-27
US20090035330A1 (en) 2009-02-05
EP1881844A2 (fr) 2008-01-30
MX2007014390A (es) 2008-02-12
NO20075727L (no) 2008-02-15
BRPI0610061A2 (pt) 2016-11-29
JP2008540625A (ja) 2008-11-20
WO2006123155A3 (fr) 2007-07-19
IL187008A0 (en) 2008-02-09
AU2006248725A1 (en) 2006-11-23
EA200702254A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
MA29459B1 (fr) Vaccins
MY149604A (en) C.perfringens alpha toxoid vaccine
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
ATE426412T1 (de) Adjuvante influenza-vakzine
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
WO2004014418A3 (fr) Composition vaccinale
MA30065B1 (fr) Vaccin
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
NZ621834A (en) Novel adjuvant compositions
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
WO2005097211A3 (fr) Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation
MA30716B1 (fr) Vaccin
WO2006065553A3 (fr) Vaccins glycoconjugues contenant un peptidoglycane
WO2006042149A3 (fr) Determination et reduction de l'immunoresistance a la therapie de la toxine botulinique a l'aide de peptides de la toxine botulinique de type a
EA201001479A1 (ru) Вакцина
ATE308992T1 (de) Attenuierte bakterien verwendbar als impstoffe
HK1106027A1 (en) Immunogenic glycopeptides for diagnosing pathogenic microorganisms infections
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
GB2444676A (en) Adjuvanted vaccine
DE60115051D1 (de) Immunologische adjuvans verbindungen
WO2006095176A3 (fr) Formulation de vaccin
SG147465A1 (en) Vaccine
WO2005013898A3 (fr) Nouvelles cibles et compositions destinees a etre utilisees dans la decontamination, l'immunoprophylaxie et le traitement post-exposition contre l'anthrax
WO2004073604A3 (fr) Vaccins adn exprimant une toxine adp-ribosyltransferase depourvue d'activite adp-ribosyltransferase